

# **Product** Data Sheet

## Morniflumate

Cat. No.: HY-17488

CAS No.: 65847-85-0Molecular Formula:  $C_{19}H_{20}F_3N_3O_3$ Molecular Weight: 395.38

Target: Others
Pathway: Others

**Storage:** 4°C, protect from light

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 125 mg/mL (316.15 mM; Need ultrasonic)

Caution: Product ha	Mass Solvent s not been fully walidated for m	1 mg edical applications. For	5 mg research use only.	10 mg
Preparing 228-6898  Stock Solution Address	Fax: 609-228-5909 <b>1 mM</b> s: 1 Deer Park Dr, Suite Q, Monm	E-mail: tech@Med 2.5292 mL outh Junction, NJ 08852	ChemExpress.com 12.6461 mL , USA	25.2921 mL
	5 mM	0.5058 mL	2.5292 mL	5.0584 mL
	10 mM	0.2529 mL	1.2646 mL	2.5292 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility:  $\geq$  2.08 mg/mL (5.26 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: 2.08 mg/mL (5.26 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.26 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description

Morniflumate (UP 164) is an orally active nonsteroidal anti-inflammatory agent. Morniflumate can be used in the study of inflammatory diseases such as osteoarthritis, painful musculoskeletal disorders and soft tissue inflammation.

#### **REFERENCES**

 $[1]. Cremonesi\ G,\ et\ al.\ Efficacy\ and\ safety\ of\ morniflumate\ for\ the\ treatment\ of\ symptoms\ associated\ with\ soft\ tissue\ inflammation.\ J\ Int\ Med\ Res.\ 2015\ Jun; 43(3):290-302.$